Imeglimin

Imeglimin is a unique oral antidiabetic agent that works by activating ATP-sensitive potassium (KATP) channels in the pancreatic beta cells. This leads to a decrease in glucose production and an increase in insulin secretion, ultimately helping to lower blood glucose levels in patients with type 2 diabetes.
Imeglimin is a first-in-class glucose-lowering therapy that offers a novel mechanism of action compared to other available treatments. Its efficacy and safety have been demonstrated in various clinical trials, making it a valuable option for patients with type 2 diabetes who have inadequate glycemic control despite receiving maximally tolerated doses of other antidiabetic agents.
The unique mechanism of action of imeglimin offers several potential advantages over existing treatments. For example, it does not cause hypoglycemia (low blood sugar), a common side effect of many diabetes medications. Additionally, imeglimin does not stimulate insulin release, which may be beneficial for patients who have experienced weight gain or hypoglycemia with other antidiabetic agents.